Guido Perez, MD
General Practice · Miami, FLNPI 1740205806
Payments from drug & device makers
Across 621 payments — averaging $2982.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1.4M
- GSK$153K
- Amgen$102K
- AstraZeneca$77K
- Astrazeneca AB$56K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$39K
- plus $65K from 3 others
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 570 | $1,359,116 |
| GSK | 31 | $152,782 |
| Amgen | 4 | $102,095 |
| AstraZeneca | 5 | $77,240 |
| Astrazeneca AB | 2 | $56,280 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $39,095 |
| Eli Lilly | 3 | $38,292 |
| Novartis | 2 | $23,297 |
| Teva Pharmaceuticals USA, Inc. | 2 | $3,750 |
How this compares
$1,851,947 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 33 | $15,094 |
| OzempicSemaglutide | 13 | $10,958 |
| JardianceEmpagliflozin | 19 | $9,529 |
| EliquisApixaban | 13 | $5,700 |
| Temazepam | 12 | $1,020 |
| Rosuvastatin Calcium | 36 | $752 |
| NitrofurantoinNitrofurantoin Macrocrystal | 19 | $545 |
| Pentoxifylline | 18 | $341 |
| Pantoprazole Sodium | 57 | $317 |
| Levothyroxine Sodium | 46 | $287 |
| Bumetanide | 20 | $285 |
| Celecoxib | 13 | $232 |
| Losartan Potassium | 24 | $224 |
| Sucralfate | 17 | $223 |
| Omeprazole | 31 | $214 |
Paid to pharmacies, not to this prescriber.
Other general practice in Miami
- Jose CardonaMiami$71M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Hector RodriguezMiami$12.8M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Omar BenitezMiami$6.9M
- Sara LlerenaMiami$6.3M
- Ana AcostaMiami$6.3M
- Gil Fernandez-YeraMiami$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.